Multiple growth pills should keep Natco Pharma's revenue charts healthy

The company has a strong product portfolio both in the domestic as well as the US markets

The Natco Pharma stock was up six per cent in two trading sessions on expectations of a strong March quarter performance and near-term triggers such as approval for generics of multiple sclerosis drug Copaxone. For the March quarter, while the pharma sector is expected to report single-digit revenue and flat net profit growth, Natco Pharma could witness a growth of 24 per cent in revenues and 117 per cent rise in its bottom line. The better performance is due to the launch of the generic version of influenza drug Tamiflu in December 2016 in the US. The drug, marketed by